|
Patent landscape, scope, and claims: |
United States Patent 8,063,043 Scope and Claims: Diphosphate Salt of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy)[1,1’-biphenyl]-3-carboxamide
US Patent 8,063,043 is directed to a narrowly defined diphosphate salt of a specific substituted carboxamide (the “salt drug substance”), and to a corresponding pharmaceutical composition using that salt with standard excipients. Claim scope is driven by (i) the exact chemical identity of the cationic base and (ii) the counterion specification as a diphosphate. The estate’s practical value for generic, salt-form, and formulation developers is that it can read across any formulation that uses the claimed diphosphate salt, even if tablet, capsule, or other dosage form changes, as long as the active ingredient is the claimed salt.
What does US Patent 8,063,043 claim as the active ingredient?
Claim 1 covers the following chemical species:
- A diphosphate salt of
N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide.
Key scope determinants in Claim 1
-
“Diphosphate salt” limits the counterion
- The claim is not a generic salts claim. It is constrained to the diphosphate counterion form.
- If a competitor uses a different counterion salt (e.g., acetate, hydrochloride, methanesulfonate, sulfate, phosphate mono-salt, etc.), the literal language does not map to Claim 1.
-
Exact base structure is required
- The base is defined by a long, specific structural identifier: the pyridine substitution pattern, the cis-2,6-dimethylmorpholin-4-yl group, the 2-methyl on the carboxamide-containing biphenyl system, and the 4’-(trifluoromethoxy) substituent.
- The scope is restricted to the claimed base scaffold and does not extend to other analogs lacking any of these elements.
-
Stereochemical language narrows the “cis” isomer
- The base includes a cis stereochemical descriptor for the morpholine ring substituent. This can reduce coverage if an alternative salt form is prepared from a different stereoisomer.
Claim 1 coverage impact for challengers
- A generic developer that switches to a different salt form (other than diphosphate) has a direct non-infringement pathway against Claim 1 based on counterion mismatch.
- A developer using the same base scaffold but different stereochemistry may also reduce literal infringement risk because Claim 1 explicitly requires the “cis” morpholine descriptor.
- A developer using the claimed diphosphate salt cannot avoid Claim 1 by changing excipients alone.
How broad is Claim 2 for formulations of the diphosphate salt?
Claim 2 adds a formulation-level claim:
- A pharmaceutical composition comprising
- (a) a therapeutically effective amount of the salt according to Claim 1; and
- (b) at least one pharmaceutically acceptable carrier, diluent, vehicle, or excipient.
What Claim 2 covers (and what it does not)
- Covers: essentially any conventional oral or non-oral dosage-form composition that contains the claimed diphosphate salt in therapeutically effective amounts plus standard excipients.
- Does not require: a specific dosage form type, release mechanism, particle size, polymorph, manufacturing method, or specific excipient identity, unless the specification independently injects limitations (not provided here).
- Consequently: Claim 2 is broad at the composition layer. If the active ingredient is still the diphosphate salt, Claim 2 is a straightforward infringement hook for many formulation variants.
Formulation workarounds
- Use a non-diphosphate salt form to avoid both Claim 1 and Claim 2 literal coverage.
- If one remains on the diphosphate salt, formulation changes likely do not eliminate infringement unless the active ingredient identity is altered (for example, switching to a different salt even within a “phosphate” family).
What are the practical infringement risks for generic or biosimilar-like “salt” products?
Even without knowing the marketed product name, the infringement map from Claim 1 and Claim 2 is predictable:
Literal infringement likely if
- The product’s API is the diphosphate salt of the exact described carboxamide base.
- The dosage form includes the salt at therapeutically effective amounts with normal carriers or excipients.
Literal infringement less likely if
- Counterion is changed from diphosphate to another anion species.
- The underlying base is not the exact compound named in Claim 1.
- Stereochemistry differs from the “cis” descriptor (if relevant to the prepared base and salt identity).
Equivalents theories
- If a competitor uses a salt that is argued to be equivalent to “diphosphate” in function, the claim language “diphosphate salt” remains a strong textual anchor against broad equivalency arguments. Equivalents analyses turn heavily on prosecution history and claim construction, which are not provided here.
How does the claim structure shape patent landscape leverage?
The patent is a classic salt-form + formulation structure:
- Compound claim (salt identity): Claim 1.
- Composition claim (API + excipients): Claim 2.
That structure typically provides:
- A clear, high-value target for enforcement against products using the claimed salt.
- A relatively narrow chemical boundary that reduces “accidental” read-on by non-identical salts.
What matters for enforcement strategy
- Chemical analytics in litigation: proving the accused API is the claimed diphosphate salt.
- If the accused product uses different polymorphs or different crystal forms, Claim 1 still hinges on salt identity, not polymorph identity, unless the claim/specification ties polymorph to infringement (not provided).
Are there design-around options that avoid Claim 1 without changing the base scaffold?
Yes, based on counterion limitation:
Counterion change is the primary design-around
- Replace diphosphate with another salt form.
- Replace the salt form with a non-diphosphate counterion that does not contain the “diphosphate” anion as claimed.
Stereochemistry and scaffold changes
- If a different stereoisomer or analog is used, the complex structural limitation in Claim 1 can be avoided by design.
Formulation changes alone are not enough
- Claim 2 requires only a therapeutically effective amount of Claim 1 salt plus excipients. Changing dosage form, binder, disintegrant, coating, or manufacturing method does not move the infringement needle unless the API salt changes.
What patent expiration and exclusivity timelines apply to US 8,063,043?
No filing and priority dates, term adjustments, or patent maintenance statuses were provided. Without them, an accurate expiration date cannot be computed from the claim text alone.
What would an ANDA Paragraph IV or 505(b)(2) strategy look like against this patent?
A generic strategy typically aligns to the claim gating issue:
Best-case legal position
- File with a product formulation using a different salt than the diphosphate salt in Claim 1.
- If that is achieved, both Claim 1 and Claim 2 are avoided on literal identity grounds.
Litigation focal points
- Whether the accused active is truly the diphosphate salt.
- Whether the salt identity matches Claim 1’s defined chemical species.
If the applicant remains on the same salt
- The applicant would face Claim 2 risk immediately because it covers any composition containing the claimed salt plus any pharmaceutically acceptable excipient.
Which companies are likely practicing or challenging this salt patent?
No assignee, specification, prosecution history, or Orange Book linking to an approved product was provided in the prompt. Without those identifiers, company-specific landscape mapping cannot be produced correctly.
What formulations are protected, and does Claim 2 cover controlled-release or dosage-form variants?
Claim 2 is broad but depends on what appears in the allowed claim set:
- It requires only:
- therapeutically effective amount of the claimed salt; and
- at least one pharmaceutically acceptable carrier/diluent/vehicle/excipient.
Protected formulation scope (from claim language)
- Immediate-release tablets, capsules, oral liquids, parenteral solutions, etc. are all conceptually within scope as long as they contain the claimed diphosphate salt and excipients.
Potential limitations from the specification
- Specifications often restrict examples, particle sizes, or preferred excipients. Those can narrow practical reach during claim construction. The specification text is not provided, so only claim-language scope can be stated reliably.
How strong is the patent estate for this invention, based on claim form?
Based solely on the two provided claims:
- Strength for enforcement: medium-to-high against products using the exact claimed diphosphate salt, because Claim 2 is formulation-agnostic and Claim 1 directly identifies the API salt.
- Strength for broad blocking: lower than broad Markush salt families because the counterion is specifically “diphosphate,” not “phosphate” or “phosphates” generally.
- Strength against close variants: relies on whether design-arounds can use alternate counterions or structural changes while maintaining therapeutic equivalence.
Key Takeaways
- US 8,063,043 Claim 1 is limited to a diphosphate salt of a single, precisely defined cis-morpholinyl, trifluoromethoxy, substituted carboxamide.
- US 8,063,043 Claim 2 broadly covers any pharmaceutical composition containing a therapeutically effective amount of that diphosphate salt plus standard pharmaceutically acceptable excipients.
- The main design-around is changing the salt counterion away from diphosphate; changing excipients or dosage-form format alone does not remove Claim 2 risk.
- A reliable expiration/exclusivity date, assignee-driven landscape, Paragraph IV likelihood by company, and FDA/Orange Book status cannot be produced from the provided information.
FAQs
-
Does US 8,063,043 cover phosphate salts generally or only a diphosphate counterion?
Only the salt explicitly described as a diphosphate salt is covered by Claim 1.
-
Can a generic avoid infringement by using different excipients while keeping the same API salt?
No. Claim 2 only requires pharmaceutically acceptable carriers/diluents/vehicles/excipients plus the claimed salt.
-
If a product uses the same base compound but a different anion salt, does it still infringe Claim 1?
Literal infringement depends on whether the API is the diphosphate salt; a different counterion generally does not map to Claim 1.
-
Does Claim 2 require any specific dosage form, release profile, or manufacturing method?
No. Claim 2 requires only the claimed salt plus at least one pharmaceutically acceptable excipient.
-
What is the core evidentiary battle in enforcement of salt-form patents like this?
Whether the accused product API is analytically the claimed diphosphate salt of the exact base specified in Claim 1.
References
- USPTO. US Patent No. 8,063,043. Claims 1-2 (as provided in prompt).
More… ↓
⤷ Start Trial
|
